The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable anticipation within the sector. A shift away from Schedule I status, often considered as outdated read more and hindering advancement, could unlock significant avenues for companies. Reduced regulatory restrictions, alongside greater access to